Tokai Pharmaceuticals has been chasing after the big players in the prostate cancer field with the idea of combining some of the best features of their drugs into a single pill. Now, with that lead drug candidate, galeterone, on the precipice of a late-stage trial, it’s taking that pitch to Wall Street.
Cambridge, MA-based Tokai has filed papers outlining plans to raise up to $75 million in an IPO.
Help employers find you! Check out all the jobs and post your resume.
